Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directe…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, C | ||
 Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls | TThe Fly | |
 Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could reshape how investors approach the week ahead. | ||
 Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value? Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss, and revenue ahead of market estimates. See our latest analysis for Madrigal Pharmaceuticals. Despite solid interest in Rezdiffra and pipeline updates, Madrigal Pharmaceuticals’ share price has slipped recently, with the 30 day share price return down 8.16% and the year to date share price... | ||
 MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth. | ||
 Madrigal Pharmaceuticals Q2 Earnings Call Highlights Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH. The company sai | ||
 Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings. | ||
 MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra. | ||
IInsider Monkey | ||
IInsider Monkey | ||